| Project/Area Number |
16591232
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kanazawa Medical University |
|---|
Principal Investigator |
HIGASHI Kotaro Kanazawa Medical University, Radiology, Professor, 医学部, 教授 (50189750)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UEDA Yoshimichi Kanazawa Medical University, Pathology, Professor, 医学部, 教授 (50271375)
TOGA Hirohisa Kanazawa Medical University, Internal Medicine, Professor, 医学部, 教授 (90142554)
|
|---|
| Project Period (FY) |
2004 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2006: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2005: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2004: ¥1,600,000 (Direct Cost: ¥1,600,000)
|
|---|
| Keywords | FDG PET / lung adenocarcinoma / angiogenesis / hypoxia inducible factor / glucose transporter / DNA microarray / hypoxia / molecular targeting therapy / hypoxia inducible factor / hypoxia / 肺癌 / VEGF / angiopoietin / mRNA / Real-time RT PCR / 新生血管 / 抗CD31抗体 / 抗CD105抗体 / hypoxia induced factor |
|---|
| Research Abstract |
Twenty-nine patients with lung adenocarcinoma underwent FDG PET before operation. Using immunohistochemical staining method, we analyzed the protein level of glucose transporter-1 and hypoxia inducible factor 2α. The protein level of glucose transporter-1 and hypoxia inducible factor 2α had a significant correlation with FDG uptake. Using DNA microarray method, we analyzed gene expression of glucose transporter-1 and Hypoxia inducible factor 2α. The gene expression of glucose transporter-1 and Hypoxia inducible factor 2α had a significant correlation with FDG uptake. These results suggest that FDG uptake of lung adenocarcinoma was affected by hypoxia, and in hypoxic condition, glucose transporter-1 expression increase. It is possible to estimate gene expression related molecular targeting therapy using FDG PET.
|
